Andrew Robbins is the CEO and President of Cogent Biosciences, a company he joined in October 2020. He has a strong background in the pharmaceutical industry, particularly in oncology and hematology. Andrew holds an MBA from the Kellogg School of...
Andrew Robbins is the CEO and President of Cogent Biosciences, a company he joined in October 2020. He has a strong background in the pharmaceutical industry, particularly in oncology and hematology. Andrew holds an MBA from the Kellogg School of Management at Northwestern, which complements his practical experience. Previously, he was the Chief Operating Officer at Array BioPharma until its acquisition by Pfizer. Under his leadership, Cogent continues to focus on developing therapies for genetically defined diseases. In 2023, his total compensation was around $1 million. Notably, when Andrew joined the company, he was awarded a significant option inducement grant, demonstrating the trust placed in him to drive the company's growth. He currently holds a significant number of shares in Cogent, reflecting his commitment to the company's future. Additionally, he serves on the board of other biotech firms, where he shares his expertise.